Postdischarge adverse drug event risk is amplified by frequent medication changes, formulary substitutions, and insurance ...
Phase Ib Study of BI 836880 (VEGF/Ang2 nanobody) in Combination With Ezabenlimab (anti–PD-1 antibody) in Patients With Advanced or Metastatic Solid Tumors From December 2022 to January 2025, one MRT ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果